Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Place of ANTI-VEGF in Diabetic Macular Edema

Diabetik MakülaÖdemindeANTİ-VEGF'lerin Yeri

Pages
43–49
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the use of anti VEFG agents in the treatment of DME was evaluated

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic macular edeme (DME) is an important complication that affecting the vision in diabetic patients.
📊
Key Findings & Data:Focal or grid laser photocoagulation has been the standart treatment options for DME.
💡
Conclusion & Impact:In this review, the use of anti VEFG agents in the treatment of DME was evaluated
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic macular edeme (DME) is an important complication that affecting the vision in diabetic patients. Focal or grid laser photocoagulation has been the standart treatment options for DME. Recently, anti VEGF agents have been used in the treatment of DME with increasing frequency. In this review, the use of anti VEFG agents in the treatment of DME was evaluated

Özet

Diabetik maküler ödem (DMÖ), diyabetik hastalarda görmeyi etkileyen önemli bir komplikasyondur. DMÖ'de fokal veya grid lazer fotokoagülasyon standart tedavi seçeneğidir. Son yıllarda ise anti-VEGF ajanlar giderek artan sıklıklıkta diyabetik makülar ödem tedavisinde kullanılmaya başlamıştır. Bu derlemede DMÖ tedavisinde anti-VEGF ajanların kullanımı değerlendirilmiştir

🔖

Cite This Article

ORUÇ, S. D., ÇAKMAK, H. (2015). Place of ANTI-VEGF in Diabetic Macular Edema. Retina-Vitreus, Cilt: 23 - Sayı: 0, 43–49. https://ajindex.com/articles/308046

References (14)

  1. Kempen JH, O'Colmain BJ, Leske MC, et al, Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63.
  2. Papavasileiou E, Dereklis D, Oikonomidis P, et al. An effective prog- ramme to systematic diabetic retinopathy screening in order to reduce diabetic retinopathy blindness. Hell J Nucl Med 2014;17:30-4.
  3. Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in dia- betic retinopathy. Middle East Afr J Ophthalmol 2013;20:293-300.
  4. Stur M, Egger S, Haas A, et al. Diagnosis, therapy and follow up of dia- betic eye disease. Wien Klin Wochenschr 2012;124:50-7.
  5. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and di- abetic macular edema. Curr Diab Rep 2012;12:346-54.
  6. Shamsi HN, Masaud JS, Ghazi NG. Diabetic macular edema: New pro- mising therapies. World J Diabetes 2013;4324-38. Photocoagulation for diabetic macular edema. Early Treatment Diabe- tic Retinopathy Study report number 1. Early Treatment Diabetic Re- tinopathy Study research group. Arch Ophthalmol 1985;103:1796-806.
  7. Caldwell RB, Bartoli M, Behzadian MA, et al.Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55.
  8. Sander B, Larsen M, Moldow B, et al. Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. In- vest Ophthalmol Vis Sci 2001;42:433-8.
  9. Tarr JM, Kaul K, Chopra M, et al. Pathophysiology of Diabetic Retino- pathy. ISRN Ophthalmol 2013;34:35-60.
  10. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-24.
  11. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-7.
  12. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110:1690-6.
  13. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
  14. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macu- lar edema: the 36-month results from two